Drug Trends and Shifting Landscapes in 2025 and Beyond
Our panel of frontline RxSS Roundtable experts weighs in on key issues for payers and patients in 2025—from a political, ...
- Select Category
- Chronic Conditions
- Engagement
- Events
- Healthcare Costs
- Media
- Medication Adherence
- Member Stories
- Our Team
- Privacy and Security
- Product
- Success Stories
- Thought Leadership
- Transparency
- Uncategorized
- Select Category
- Chronic Conditions
- Engagement
- Events
- Healthcare Costs
- Media
- Medication Adherence
- Member Stories
- Our Team
- Privacy and Security
- Product
- Success Stories
- Thought Leadership
- Transparency
- Uncategorized
How Payers Can Leverage the Cash Pharmacy and Discount Card Trend
Consumers have more choices for purchasing prescriptions without insurance. How can plans capture what they're ...
More Patients Turning to Cash Pharmacies and Discount Cards
Patients and plans both benefit from better medication access, affordability and adherence. Cash pharmacies and ...
Prescription Delivery and Digital Pharmacies Consumer Adoption
The pandemic brought an uptick in prescription deliveries, yet they still lag behind most other ...
7 Easy-to-Influence Survey Responses for Better Medicare Advantage Star Ratings
It’s too late to do anything about 2023 Medicare Star ratings. But it’s never too ...
The Great 2023 Humira Biosimilars Watch Is On – Here’s Where to Focus
Up to 10 competing products for Humira are on the way in 2023. What should ...
Diabetes by the Numbers, and the Importance of Affordable Medication
Some lesser-known facts about this chronic condition underscore the importance of medication adherence, and the ...
A Q&A on the IRA
The Inflation Reduction Act has the potential to lower prescription drug costs for millions of ...
The Adderall Shortage Is Real – Here’s How RxSS Helps Members
We know many members are scrambling to find pharmacies with the common ADHD medication in ...
Humira Biosimilars and other Biologic Alternatives
A wave of FDA-approved biosimilars for Humira and other costly biologics will enter the U.S. ...
Stay COnnected
Share your email and once a month we’llsend you industry news and insights.
